友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.
武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

SUPPLEMENTAL ANNOUNCEMENT
DISCLOSEABLE TRANSACTION
TRANSFER OF LAND USE RIGHT AND BUILDING

Reference is made to the announcement (the "**Announcement**") of Wuhan YZY Biopharma Co., Ltd. (the "**Company**") dated January 23, 2026 in relation to the Transfer of Land Use Right and Building. Capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

The Company would like to provide further information in relation to the Transfer.

(1) Original intended purpose of the Land Use Right and the Building

The Land Use Right was acquired in 2012. At that time, it was planned for the construction of facilities for the manufacturing of the Group's products (including M701) in the Mainland *after* their commercialisation.

However, for reasons out of the Group's control (including delay in delivery of such land parcel by the Wuhan Bureau of Natural Resources and Planning and the impact of COVID), construction was delayed.

In the past decade, the development of contract manufacturing organizations ("**CMOs**")/contract development and manufacturing organizations ("**CDMOs**") has accelerated in Mainland China. Considering the status of the Group's pipeline candidates and the expected manufacturing volume required for their development, outsourcing the manufacturing of commercialised products to third-party CMOs/CDMOs could be more efficient than in-house manufacturing of the relevant products.

Reference is also made to the announcement of the Company dated October 7, 2024. In 2024, the Company granted to a third party an exclusive, sublicensable license to develop, register, manufacture and commercialize M701.

M701 is in the more advanced phase of clinical trials, as compared to the other drug candidates of the Group, which are in stages of research and development ("**R&D**") or earlier phases of clinical trials.

As at the date of this announcement and upon completion of the Transfer, the Group owns and will continue to own facilities which can satisfy the preclinical studies and earlier phases of clinical trials for its drug candidates.

For the above reasons, the Land Use Right and the Building were no longer required by the Group for its original intended purpose.

(2) Impact of the Transfer

The Transfer has no impact on the Company's business plans and operations, including R&D and commercialisation activities.

Under the licence agreement, the commercialisation of M701 has been licensed exclusively to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (正大天晴藥業集團股份有限公司).

The Company continues to focus on the development of its other drug candidates including Y101D, Y332, Y225, Y232 and other pre-clinical assets. None of these require the usage of the Land Use Right or the Building.

(3) Use of proceeds

Assuming the Company receives the maximum consideration of RMB36,880,000, it is expected that the net proceeds (taking into account the tax, duties and fees incurred in connection with the Transfer) would be not more than approximately RMB24,600,000.

Based on the current development status of its core products and information available, it is expected that the net proceeds will be applied as follows.

Intended Use	**Approximate percentage of net proceeds**	**Amount** *(RMB)*	**Utilization timeline**
Research and development (R&D)	—	—	—
Clinical research and development- includes clinical trials, data monitoring, and registration applications for products that have entered the clinical stage	34.51%	8,490,000	2026 and 2027
Early stage R&D development- includes early stage R&D activities such as discovery of new product targets, drug candidate screening, preclinical research, and patent strategy	40.49%	9,960,000	2026 and 2027
	75%	18,450,000	
Working capital and general corporate purposes (including salaries, professional fees, repay the bank loan and office administration expenses)	25%	6,150,000	2026 and 2027

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, February 5, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.